The first results obtained using a SOI device for microdosimetry applications are presented. Microbeam and broadbeam spectroscopy methods are used for determining minority carrier lifetime and radiation damage constants. A spectroscopy model is presented which includes the majority of effects that impact spectral resolution. Charge collection statistics were found to substantially affect spectr...

An ion transport code was developed for simulating ionization energy deposition by energetic ions in sensitive volumes of complex structures. The code was used to simulate recent microdosimetry measurements performed with silicon-on-insulator (SOI) microdosimeters in Fast Neutron Therapy (FNT).

Dr. Goodhead proposes to give in his review "a perspective of the evolving role of microdosimetry in the study of radiation effects in mammalian cells," but he also states his intention to "confine this paper to the earlier more narrow usage," i.e., the site concept. A treatment that focuses on a first step that was presented more than a decade ago hardly provides a perspective on a developing ...

Preclinical studies for boron neutron capture therapy (BNCT) using epithermal neutrons are ongoing at several laboratories. The absorbed dose in tumor cells is a function of the thermal neutron flux at depth, the microscopic boron concentration, and the size of the cell. Dosimetry is therefore complicated by the admixture of thermal, epithermal, and fast neutrons, plus gamma rays, and the array...

Fast neutrons (FN) have a higher radio-biological effectiveness (RBE) compared with photons, however the mechanism of this increase remains a controversial issue. RBE variations are seen among various FN facilities and at the same facility when different tissue depths or thicknesses of hardening filters are used. These variations lead to uncertainties in dose reporting as well as in the compari...

Targeted alpha therapy (TAT) has the advantage of delivering therapeutic doses to individual cancer cells while reducing the dose to normal tissues. TAT applications relate to hematologic malignancies and now extend to solid tumors. Results from several clinical trials have shown efficacy with limited toxicity. However, the dosimetry for the labeled alpha particle is challenging because of the ...